<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T04:23:03Z</responseDate>
  <request identifier="oai:figshare.com:article/33998600" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33998600</identifier>
        <datestamp>2026-09-25T17:33:18Z</datestamp>
        <setSpec>category_13</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_61</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Functional PTGS candidate classes defined by consequence-first prioritisation.&lt;/p&gt;</dc:title>
          <dc:creator>Reuben S. Maghembe (24764031)</dc:creator>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Developmental Biology</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>structured coding variation</dc:subject>
          <dc:subject>shell position adjacent</dc:subject>
          <dc:subject>peptide predictor output</dc:subject>
          <dc:subject>comparative evolutionary pharmacogenomics</dc:subject>
          <dc:subject>canonical val511 mapped</dc:subject>
          <dc:subject>calibrated prioritisation framework</dc:subject>
          <dc:subject>resolved population differentiation</dc:subject>
          <dc:subject>describe population differentiation</dc:subject>
          <dc:subject>sequence property calculations</dc:subject>
          <dc:subject>sequence missense variants</dc:subject>
          <dc:subject>regulate prostaglandin biosynthesis</dc:subject>
          <dc:subject>prediction boundary checks</dc:subject>
          <dc:subject>proline count across</dc:subject>
          <dc:subject>aware consequence annotation</dc:subject>
          <dc:subject>controlled structural analyses</dc:subject>
          <dc:subject>study integrated allele</dc:subject>
          <dc:subject>terminal ptgs1 leader</dc:subject>
          <dc:subject>residue leader sequence</dc:subject>
          <dc:subject>terminal leader</dc:subject>
          <dc:subject>residue count</dc:subject>
          <dc:subject>interpreting population</dc:subject>
          <dc:subject>structural context</dc:subject>
          <dc:subject>prediction evidence</dc:subject>
          <dc:subject>human prostaglandin</dc:subject>
          <dc:subject>controlled docking</dc:subject>
          <dc:subject>transcript consequence</dc:subject>
          <dc:subject>tested conditions</dc:subject>
          <dc:subject>systematic variant</dc:subject>
          <dc:subject>srp recognition</dc:subject>
          <dc:subject>retrospective comparison</dc:subject>
          <dc:subject>results support</dc:subject>
          <dc:subject>ranked first</dc:subject>
          <dc:subject>ptgs1 p</dc:subject>
          <dc:subject>pangolin evaluation</dc:subject>
          <dc:subject>nsaids ).</dc:subject>
          <dc:subject>nonsteroidal anti</dc:subject>
          <dc:subject>membrane insertion</dc:subject>
          <dc:subject>mean kyte</dc:subject>
          <dc:subject>major targets</dc:subject>
          <dc:subject>inflammatory drugs</dc:subject>
          <dc:subject>frequency structure</dc:subject>
          <dc:subject>frequency range</dc:subject>
          <dc:subject>er targeting</dc:subject>
          <dc:subject>enzyme activity</dc:subject>
          <dc:subject>drug response</dc:subject>
          <dc:subject>doolittle hydropathy</dc:subject>
          <dc:subject>domain mapping</dc:subject>
          <dc:subject>direct leader</dc:subject>
          <dc:description>&lt;p&gt;Functional PTGS candidate classes defined by consequence-first prioritisation.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-25T17:33:08Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.pone.0358222.t001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_Functional_PTGS_candidate_classes_defined_by_consequence-first_prioritisation_p_/33998600</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
